



InteliCare Holdings Ltd
ABN 84 622 484 397

ASX Code
ICR

Corporate Directory

Non-Executive Chair
Dr Neale Fong

Non-Executive Director
Mr Greg Leach

Interim Executive Director
Mr Tim Chapman

Company Secretary
Mr Neil Hackett

Chief Executive Officer
Mr Daniel Pilbrow

Issued Shares
487,338,144

Unlisted Options
(including Perf Rights)
161,842,857

Listed Options
81,176,732

Company Details
Email
investors@intelicare.com.au

Website
www.intelicare.com.au

Registered & Principal Office
Level 1, 299 Vincent St
Leederville WA 6001

InteliCare completes \$2 million placement to accelerate growth

HIGHLIGHTS

- ICR has received firm commitments to raise \$2 million via a two-tranche placement at 1.5 cents per new share;
- Commitments have been received from both existing and new institutional and sophisticated professional investors
- Under Tranche One, 121,834,000 fully paid ordinary shares will be issued immediately under ICR's existing LR7.1 & 7.1A capacity raising approximately \$1.827m;
- Under Tranche Two, 11,500,000 fully paid ordinary shares will be issued, subject to shareholder approvals at an upcoming EGM, raising the balance of approximately \$173,000;
- As part of this capital raising, the \$600,000 convertible note facility, entered into and announced on 9 July 2025, has been terminated with all subscribers to the facility entering into a deed of termination; and
- Proceeds will support the Company's growth strategy allowing for ICR to accelerate deployments for potential new customers in the pipeline and provide working capital to support pilot programs.

InteliCare Holdings Ltd ("ICR" or the "Company") (ASX: ICR), an Australian Software-as-a-Service (SaaS) technology company commercialising its proprietary AI driven InteliCare platform (InteliCare) in the aged care, disability and health sectors is pleased to announce it has received firm commitments to raise \$2 million via a two-tranche private placement (Placement) to institutional and sophisticated professional investors.

Tim Chapman, Interim Executive Director, says: "We are grateful for the continued support of the Company from its existing shareholders and welcome new shareholders. The extra funds received from this Placement will be used to continue to support our incredibly exciting pilot with mecware, our continued deployment at Hardi Aged Care, further enhancements to our market leading platform, deliver further commercial agreements with key groups in the Company's sales pipeline and working capital.

With key deployments in place we are building a compelling evidence base as to the value proposition of our InteliCare platform. InteliCare is improving care outcomes, driving staffing productivity and efficiencies, improving asset management as well as resident engagement, all supported by our leading AI models. InteliCare will be at the forefront of how Aged Care will be delivered into the future.

By also terminating the convertible note facility, we have simplified the Company's capital structure and are well positioned to continue delivering growth. I look forward to updating shareholders as we progress with mecware, Hardi Aged Care and others."

Tranche 1 of the Placement will be completed under the Company's ASX LR 7.1 and 7.1A placement capacity raising approximately \$1.827m (before costs) via the issue of 121,834,000 new fully paid ordinary shares at 1.5 cents per share. Tranche 2 of the Placement will be completed, subject to shareholder approval at an upcoming EGM to approve the issue of 11,500,000 new fully paid ordinary shares raising the balance of approximately \$172,000 at 1.5 cents per share. The Placement was completed with professional and sophisticated investors within section 708(8) and section 708(11) of the Corporations Act (Cth).

As part of this capital raising, the \$600,000 convertible note facility entered into and announced July 7th, 2025 has been terminated with all subscribers to the facility entering into a deed of termination with the Company. The convertible note facility terminated would have been significantly more dilutionary than this capital raising.

Westar Capital Ltd acted as lead manager to the capital raising and received a 6% capital raising fee. Westar (or its nominee) will also receive 20 million options with an exercise price of 2.0 cents and an expiry date three years from the date of issue, subject to a shareholder approval to be sought at the upcoming EGM being held to approve Tranche 2 of the Placement.

This announcement is designed to lift the current trading halt in IntelliCare's securities.

ENDS

THIS ANNOUNCEMENT IS DESIGNED TO LIFT THE CURRENT TRADING HALT IN ICR SECURITIES

This announcement is approved for release by the Board of IntelliCare Holdings Limited.

For more information regarding IntelliCare, visit www.intellicare.com.au.

Contact and Authorised for Release to the ASX

Daniel Pilbrow, Chief Executive Officer, IntelliCare Holdings Ltd, +61 1300 001 145,
investors@intellicare.com.au

About Intellicare Holdings Limited

IntelliCare is an Australian technology company that has commercialised a predictive analytics hardware and software system for use in the aged care and health industries. IntelliCare believes Australians deserve to age with dignity and through its business-to-business (B2B) and business-to-consumer (B2C) solutions built on its proprietary internet of things (IoT) platform utilising smart sensors and artificial intelligence (AI), IntelliCare aims to enable people to stay in their own homes for longer while empowering healthcare providers to deliver higher quality, more efficient services.